Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity

Journal of Allergy and Clinical Immunology

Volumn 103, Issue 3 II, 1999, Pages 427-435

  FitzGerald, J Mark ^a,g   Chapman, Kenneth R ^b   Cioppa, Giovanni Della ^c   Stubbing, David ^d   Fairbarn, Mary Sue ^e   Till, M Denise ^c   Brambilla, Reto ^f  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e British Columbia Lung Association   (Canada)

^f NOVARTIS PHARMA AG   (Switzerland)

^g MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Asthma; Asthma control; Tolerance; agonists

Indexed keywords

ANTIASTHMATIC AGENT; ANTIHISTAMINIC AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FORMOTEROL; METHACHOLINE; NEDOCROMIL; SALBUTAMOL; XANTHINE DERIVATIVE;

ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYMPTOMATOLOGY;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; SAFETY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0033013813     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(99)70467-7     Document Type: Article

References (46)

1. Sears MR, Taylor DR. Regular β-agonist therapy - the quality of evidence. Eur Respir J 1992;5:896-7.
2. Page C, Costello J. Controversies in respiratory medicine: regular inhaled β-agonists - Clear clinical benefit or hazard to health? (2) Why β-agonists should not be used regularly. Respir Med 1992;86:477-9.
3. 2-agonists in asthma: Much ado about nothing? Still cause for concern. BMJ 1994;109:794-5.
4. Taylor DR, Sears MR. Regular β-adrenergic agonists: evidence, not reassurance, is what is needed. Chest 1994;106:552-9.
5. Sears MR. Is the routine use of inhaled β-adrenergic agonists appropriate in asthma treatment? No. Am J Respir Crit Care Med 1995;151:600-1.
6. Crane J, Pierce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989;1:917-22.
7. Crane J, Pearce N, Burgess C, Beasley R. Asthma and the β-agonist debate. Thorax 1995;50(Suppl 1):S5-10.
8. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
9. Sears MR, Taylor DR, Print CG, et al. Regular inhaled β-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6.
10. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled β-agonists in asthma: effects on exacerbations and lung function. Thorax 1993;48:134-8.
11. van Schayck CP, Dompeling E, van Herwaarden CLA, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: Continuous or on-demand? A randomized controlled study. BMJ 1991;303:1426-31.
12. 2-agonists in asthma. N Engl J Med 1992;327:1204-8.
13. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993;342:833-7.
14. Chapman KR, Kesten S, Szalai JP. Regular vs as-needed inhaled salbutamol in asthma control. Lancet 1994;343:1379-82.
15. Nelson HS. β-Adrenergic bronchodilators. N Engl J Med 1995;333:499-506.
16. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 1996;335:841-7.
17. Burrows B, Lebowitz MD. The β-agonist dilemma. N Engl J Med 1992;326:560-2.
18. 2-adrenoceptor long-acting agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992;327:1198-2003.
19. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise-induced bronchoconstriction after chronic dosing with salmeterol. Am J Respir Crit Care Med 1994;88:363-8.
20. Bhagat R, Kalra S, Swystun V, Cockcroft D. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995;108:1235-9.
21. Yates DH, Sussman HS, Shaw MJ, Barnes PJ, Chung KF. Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment. Am J Respir Grit Care Med 1995;152:1170-4.
22. 2-adrenoceptor responses after twice daily treatment with formoterol dry powder in asthmatic patients. Thorax 1995;50:497-504.
23. Verbene AAPH, Hop WCJ, Creighton FBM, et al. Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma. J Allergy Clin Immunol 1996;97:938-46.
24. Beach JR, Young CL, Harkawat R, et al. Effect on airway responsiveness of six weeks treatment with salmeterol. Pulm Pharmacol 1993;6:155-7.
25. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992;327:1420-5.
26. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994;271:1412-6.
27. British Thoracic Society and others. Guidelines for the management of asthma: a summary. BMJ 1993;306:776-82.
28. National Asthma Education Program. Expert panel report 2 for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health; 1997. Publication no 97-4051.
29. Ernst P, FitzGerald JM, Spier S. Canadian asthma consensus conference summary of recommendations. Can Respir J 1996;3:89-100.
30. American Thoracic Society. American Thoracic Society standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
31. Cockcroft DW, Killian DN, Mellon JA, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977;7:235-43.
32. Juniper EF, Frith PA, Dunnett C, Cockcroft DW, Hargreave FE. Reproducibility and comparison of response to inhaled histamine and methacholine. Thorax 1978;33:705-10.
33. Cockcroft DW, Murdock KY, Mink JT. Determination of histamine PC20. Comparison of linear and logarithmic interpolation. Chest 1983;84:505-6.
34. Twentyman OP, Higenbottam TW. Controversies in respiratory medicine: regular inhaled β-agonists - Clear clinical benefit or a hazard to health? 1. β-Agonists can be used safely and beneficially in asthma. Respir Med 1992;86:471-6.
35. Löfdahl CG, Svedmyr N. β-Agonists - still more friends than foes. Eur Respir J 1992;5:898-900.
36. Wanner A. Is the routine use of inhaled β-adrenergic agonists appropriate in asthma treatment? Yes. Am J Respir Crit Care Med 1995;151:597-9.
37. Giuntini CG, Paggiaro PL. Present state of the controversy about regular inhaled β-agonists in asthma. Eur Respir J 1995;8:673-8.
38. 2-agonists in the treatment of asthma. N Engl J Med 1996;335:886-8.
39. Booth H, Bish R, Walters J, Whitehead F, Walters EH. Salmeterol tachyphylaxis in steroid treated subjects. Thorax 1996;51:1100-4.
40. Hui KKP, Connoly ME, Tashkin DP. Reversal of human lymphocyte β-adrenoreceptor desensitization by glucocorticoids. Clin Pharmacol Ther 1982;32:566-71.
41. 2-adrenoreceptors: accelerated restoration of β-adrenoreceptor responsiveness by prednisolone and ketotifen. J Clin Invest 1985;76:1096-101.
42. Kalra S, Swystun V, Bhagat R, Cockroft D. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996;109:953-6.
43. Vathenen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield AE. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988;1:554-7.
44. Kraan J, Koëter GH, vd Mark TW, Sluiter HJ, de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with anti-asthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985;76:628-36.
45. Kerrebijin IF, van Essen-Zandvliet EEM, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and β-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987;79:653-9.
46. Wahedna I, Wong CS, Wisniewski AFZ, Pavord ID, Tattersfield AE. Asthma control during and after cessation of regular β2-agonist treatment. Am Rev Respir Dis 1993;148:707-12.